1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6137FF78B9CB2708185257D4800627FA6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-big-data-pharma-governance-data-capabilities-medical-commercial-heor-segments?opendocument
18
19opendocument
203.80.224.52
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services ╗ Market Research, Analytics and ForecastingAnalytics

Big Data in Pharma: Governance and Data Capabilities Across Medical, Commercial & HEOR Segments

ID: 5328


Features:

12 Info Graphics

24 Data Graphics

300+ Metrics

3 Narratives


Pages/Slides: 43


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Big Data in Pharma: Governance and Data Capabilities Across Medical, Commercial & HEOR Segments"


STUDY OVERVIEW

The 21st century has seen an explosion in the availability of all types of data, including healthcare, social media and transactional information. Together, these and other types of large and complex data sets have come to be known as Big Data. Many in the pharmaceutical sector have begun to leverage these new sources and tools to generate deeper insights and to speed up their decision-making in a competitive market.

Among the many challenges facing pharma as the sector strives to develop Big Data capabilities are which functions lead and utilize Big Data, what governance system or policies should be in place, what data capabilities will need to grow, and what type of organizations are best to partner with on projects. Best Practices, LLC undertook this study to probe these questions and current trends in the pharmaceutical sector around Big Data and the issues of governance, data capabilities and partnerships.

This study provides Medical, Commercial and HEOR segmented responses on survey questions

KEY TOPICS

  • Executive Summary
  • Big Data Team Overview and Key Study Insights
  • Quantitative Key Findings
  • Defining Big Data
  • Governance and Leadership
  • Partnerships

SAMPLE KEY METRICS
  • Regions where you have Big Data capabilities and Big Data governance resides
  • North American functions that utilize and/or lead Big Data projects
  • Policies and procedures in place to govern Big Data activities
  • Internal vs. external staffing for list of nine data capabilities
  • Will your organization's data capabilities increase over the next 2 years and will resources be internally or externally increased?
  • Which partners are most impactful/valuable on Big Data projects?

SAMPLE KEY FINDING
  • The HEOR/HECOR function was the function most often using and leading Big Data projects across medical, commercial and HEOR responses. Most participants said many functions – R&D, commercial, pharmacovigilance – are using Big Data studies.
  • More than half of the medical and HEOR segments said they had 8-9 of the 12 policies listed in the survey.

METHODOLOGY

Best Practices, LLC engaged 22 leaders from 18 pharmaceutical companies through a benchmarking survey.áResearch analysts also conducted seven deep-dive executive interviews with selected benchmarká participants.

Industries Profiled:
Pharmaceutical; Health Care; Biotech; Chemical; Medical Device; Manufacturing; Consumer Products; Diagnostic; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Merck; Merck Serono; Novartis; Boehringer Ingelheim; Genentech; Teva Pharmaceutical Industries Ltd; Pfizer; Baxter Healthcare; GlaxoSmithKline ; Bayer; Gilead Sciences; Janssen; Lundbeck; Sanofi; Esteve; Daiichi Sankyo; Purdue Pharma; AstraZeneca


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.